Breaking News
Investing Pro 0
New! 💥 Get ProPicks to see the strategy that has beaten the S&P 500 by 829%+ Claim 60% Off
Close

Novo Nordisk A/S Class B (NOVOb)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
669.2 +0.6    +0.09%
02:59:53 - Closed. Currency in DKK ( Disclaimer )
  • Volume: 2,184,178
  • Bid/Ask: 0.0 / 0.0
  • Day's Range: 666.8 - 676.6
Type:  Equity
Market:  Denmark
ISIN:  DK0062498333 
S/N:  1717564000
Novo Nordisk B 669.2 +0.6 +0.09%

NOVOb Income Statement

 
Featured here, the Income Statement (earnings report) for Novo Nordisk A/S Class B, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Income Statement
Period Ending: 2023
30/09
2023
30/06
2023
31/03
2022
31/12
Total Revenue 58731 54300 53367 48092
Revenue 58731 54300 53367 48092
Other Revenue, Total - - - -
Cost of Revenue, Total 9713 7856 8182 8262
Gross Profit 49018 46444 45185 39830
Total Operating Expenses 31818 30412 28360 30194
Selling/General/Admin. Expenses, Total 14075 15414 13483 15091
Research & Development 8128 7127 6728 7325
Depreciation / Amortization 2525 2177 1719 -5327
Interest Expense (Income) - Net Operating - - - -378
Unusual Expense (Income) - - - -
Other Operating Expenses, Total -2623 -2162 -1752 5221
Operating Income 26913 23888 25007 17898
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets - - - -587
Other, Net -1150 -366 270 2169
Net Income Before Taxes 28063 24254 24737 16316
Provision for Income Taxes 5585 4826 4923 2724
Net Income After Taxes 22478 19428 19814 13592
Minority Interest - - - -
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 22478 19428 19814 13592
Total Extraordinary Items - - - -
Net Income 22478 19428 19814 13592
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items 22478 19428 19814 13592
Dilution Adjustment 33 -0.719 1.05 -10.01
Diluted Net Income 22445 19428.72 19812.95 13602.01
Diluted Weighted Average Shares 4489 4502.6 4513.2 4522.8
Diluted EPS Excluding Extraordinary Items 5 4.32 4.39 3.01
DPS - Common Stock Primary Issue - 3 - 4.08
Diluted Normalized EPS 3.91 3.37 3.43 2.45
* In Millions of DKK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NOVOb Comments

Write your thoughts about Novo Nordisk A/S Class B
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email